Welcome to Markets Desk, let's get you up to speed.
France's CAC forty is drifting lower this Monday as investors hold their breath ahead of two major catalysts — Fed Chair Kevin Warsh's speech at Jackson Hole and Nvidia's upcoming earnings report. The index briefly poked above the flat line late morning before sellers reasserted control, a sign that conviction is thin and positioning cautious heading into what could be a market-moving week.
Keeping an eye on the equity pipeline, QXO Incorporated — the building products distributor backed by Brad Jacobs — has named Ken West as President and Chief Operating Officer, effective September first. West's appointment signals QXO is building out its executive bench as the company pursues what has been an aggressive acquisition strategy in the fragmented building materials distribution space.
And in biotech, Oculis Holding is moving its lead asset forward, announcing that the first patient has been dosed in its PIONEER-one registrational trial of Privosegtor for optic neuritis. Registrational means this trial is designed to support a regulatory filing, so today's dosing is a genuine clinical milestone. Shares of OCS are trading higher on the news.
That's the tape. Markets Desk, signing off the floor.
